Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander A Vinks

Showing results (181-190 of 196) with videos related to

Pageof 20
Sort By:
Alimentary Pharmacology & Therapeutics|October 31, 2022
Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearanceRuben J Colman, Tomoyuki Mizuno, Keizo Fukushima, et al.
Therapeutic Drug Monitoring|March 13, 2018
Acute Kidney Injury Biomarkers Predict an Increase in Serum Milrinone Concentration Earlier Than Serum Creatinine-Defined Acute Kidney Injury in Infants After Cardiac SurgeryKatja M Gist, David S Cooper, Julia Wrona, et al.
Clinical Pharmacology and Therapeutics|October 17, 2019
Electronic Health Record-Embedded Decision Support Platform for Morphine Precision Dosing in NeonatesAlexander A Vinks, Nieko C Punt, Frank Menke, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2016
A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell TransplantationPooja Khandelwal, Chie Emoto, Tsuyoshi Fukuda, et al.
Bone Marrow Transplantation|September 22, 2021
A prospective pilot study of a novel alemtuzumab target concentration intervention strategyDanielle E Arnold, Chie Emoto, Tsuyoshi Fukuda, et al.
Pharmacogenetics and Genomics|April 13, 2006
Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotypeZhengwen Jiang, Nadine Dragin, Lucia F Jorge-Nebert, et al.
Pediatric Transplantation|September 5, 2017
Mycophenolate mofetil-related leukopenia in children and young adults following kidney transplantation: Influence of genes and drugsCharles D Varnell, Tsuyoshi Fukuda, Cassie L Kirby, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform NeurofibromasBrian D Weiss, Pamela L Wolters, Scott R Plotkin, et al.
Trials|November 28, 2020
Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemiaEmily R Meier, Susan E Creary, Matthew M Heeney, et al.
Neuro-Oncology|April 3, 2020
A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium studyNicole J Ullrich, Sanjay P Prabhu, Alyssa T Reddy, et al.
Pageof 20

Showing results (181-190 of 196) with videos related to

Sort By:
Pageof 20
Alimentary Pharmacology & Therapeutics|October 31, 2022
Real world population pharmacokinetic study in children and young adults with inflammatory bowel disease discovers novel blood and stool microbial predictors of vedolizumab clearanceRuben J Colman, Tomoyuki Mizuno, Keizo Fukushima, et al.
Therapeutic Drug Monitoring|March 13, 2018
Acute Kidney Injury Biomarkers Predict an Increase in Serum Milrinone Concentration Earlier Than Serum Creatinine-Defined Acute Kidney Injury in Infants After Cardiac SurgeryKatja M Gist, David S Cooper, Julia Wrona, et al.
Clinical Pharmacology and Therapeutics|October 17, 2019
Electronic Health Record-Embedded Decision Support Platform for Morphine Precision Dosing in NeonatesAlexander A Vinks, Nieko C Punt, Frank Menke, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 25, 2016
A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell TransplantationPooja Khandelwal, Chie Emoto, Tsuyoshi Fukuda, et al.
Bone Marrow Transplantation|September 22, 2021
A prospective pilot study of a novel alemtuzumab target concentration intervention strategyDanielle E Arnold, Chie Emoto, Tsuyoshi Fukuda, et al.
Pharmacogenetics and Genomics|April 13, 2006
Search for an association between the human CYP1A2 genotype and CYP1A2 metabolic phenotypeZhengwen Jiang, Nadine Dragin, Lucia F Jorge-Nebert, et al.
Pediatric Transplantation|September 5, 2017
Mycophenolate mofetil-related leukopenia in children and young adults following kidney transplantation: Influence of genes and drugsCharles D Varnell, Tsuyoshi Fukuda, Cassie L Kirby, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 28, 2021
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform NeurofibromasBrian D Weiss, Pamela L Wolters, Scott R Plotkin, et al.
Trials|November 28, 2020
Hydroxyurea Optimization through Precision Study (HOPS): study protocol for a randomized, multicenter trial in children with sickle cell anemiaEmily R Meier, Susan E Creary, Matthew M Heeney, et al.
Neuro-Oncology|April 3, 2020
A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium studyNicole J Ullrich, Sanjay P Prabhu, Alyssa T Reddy, et al.
Pageof 20